FinscoFinsco

Agios Pharmaceuticals (US.AGIO)

Capital Allocation Audit · Period: 2011 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.AGIO · YoY: 2026 H1 vs 2025 H1

MetricValueYoY
FCF Conversion115.3%↑
ROE-19.5%↓
Cash Conversion-→
D/E Ratio0.03↑
Gross Margin93.4%↑
US.AGIO (Agios Pharmaceuticals) | YoY: 2026 H1 vs 2025 H1


Metric            Value  YoY
----------------------------
FCF Conversion   115.3%    ↑
ROE              -19.5%    ↓
Cash Conversion       -    →
D/E Ratio          0.03    ↑
Gross Margin      93.4%    ↑
Key Metrics
US.AGIO (Agios Pharmaceuticals) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY
----------------------------
FCF Conversion 115.3% ↑
ROE -19.5% ↓
Cash Conversion - →
D/E Ratio 0.03 ↑
Gross Margin 93.4% ↑

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies